z-logo
Premium
Complete and long‐lasting cytologic and molecular remission of FIP 1L1‐ PDGFRA ‐ positive acute eosinophil myeloid leukaemia, treated with low‐dose imatinib monotherapy
Author(s) -
Barraco Daniela,
Carobolante Francesca,
Candoni Anna,
Simeone Erica,
Piccaluga Pierpaolo,
Tabanelli Valentina,
Fanin Renato
Publication year - 2014
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.12272
Subject(s) - eosinophil , imatinib , myeloid leukaemia , pdgfra , myeloid , medicine , immunology , chronic myeloid leukaemia , eosinophilia , myeloid leukemia , gist , cancer research , stromal cell , asthma
Myeloproliferative neoplasms associated with FIP 1L1‐ PDGFR rearrangements represent a rare subset of myeloid and lymphoid malignancies, characterised by the presence of eosinophilia and abnormalities of PDGFRA , PDGFRB or FGFR 1 genes. The fusion product of such genes is a tyrosine kinase oncoprotein sensitive to imatinib, which to date results to be the standard of care for FIP 1L1‐ PDGFRA ‐ positive chronic myeloproliferative disorders with eosinophilia. However, the coexistence of FIP 1L1‐ PDGFRA rearrangement associated with acute myeloid leukaemia is extremely rare. Here, we report a rare case of FIP 1L1‐ PDGFRA ‐ positive acute myeloid leukaemia, with marked peripheral blood and bone marrow eosinophilia, treated with low dose of imatinib monotherapy, achieving a rapid and long‐lasting complete cytologic and molecular remission, without need for intensive chemotherapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here